A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 23 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 This trial has been completed in Germany (end date: 2017-12-20)
- 24 Jan 2018 This trial was completed in Poland according to European Clinical Trials Database record.